Renal involvement is a common complication of multiple myeloma (MM). However, most studies have focused on renal failure in MM, and little information is available about the other renal manifestations in MM and their association with immunophenotypes and renal pathology.
3 respectively.
Conclusions
Renal involvement was common at MM diagnosis and had diverse clinical manifestations. Nephrologists should rule out MM in patients presenting with renal involvement.
Background
Multiple myeloma (MM) is a neoplastic, plasma-cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, the presence of monoclonal protein in the blood or urine and associated organ dysfunction. Renal involvement is one of the main clinical manifestation threatening complication in MM patients [1, 2] . Tsakiris et al. [3] reported that MM was the most common neoplasm causing end-stage renal disease, and the first malignancy to be considered an indication for dialysis. Studies on renal involvement in MM tend to focus on renal failure. Impaired renal function is a marker of poor prognosis [4] .
Multiple pathogenic mechanisms can contribute to kidney injury in MM patients; some mechanisms are the result of nephrotoxic monoclonal Ig deposition in the kidneys and others are independent of Ig deposition [5] .
However, renal involvement in MM has diverse manifestations, which include isolated proteinuria, proteinuria combined with hematuria, renal failure and renal tubular interstitial involvement. Little is known about the proportion of the different manifestations of renal involvement in MM. Studies on the relationship between immunofixation electrophoresis and renal involvement in MM patients have mainly analyzed immune phenotypes and renal failure. Patients with light chains were significantly more prone to develop renal failure (42%-52%) than patients with IgG (22%) or IgA (31%) [6] . However, the relationship between other results of immunofixation electrophoresis and renal involvement is unclear. Furthermore, we have found that most cases of MM with renal failure were reported from Departments of Hematology. Some MM patients with renal involvement as the first manifestation may be admitted in Departments of Nephrology, and the clinical features of these patients need to be studied. The first symptom of MM varies among patients, and therefore, MM can be diagnosed in different hospital departments. However, few data are available on the proportion of the various presenting symptoms of MM and of the different departments in which MM is diagnosed. In addition, little information is available on MM with renal involvement in the Chinese population. Therefore, to explore the incidence, manifestations of renal involvement, clinical, pathological characteristics and immunofixation electrophoresis features in MM in the Chinese population, we retrospectively studied 283 MM patients admitted to the Sichuan Provincial People's Hospital in West China, between January 1990 and May 2017. Here, we present the results of our analysis.
Methods
This study involved 283 MM patients who were treated in Sichuan Provincial People's Hospital, West China, between January 1990 and May 2017. Our study was approved by the Ethics Committee of the Sichuan Provincial People's Hospital.
MM was diagnosed if any two of the following criteria were met: at least 10% clonal plasma cells in the bone marrow, serum or urinary monoclonal protein and radiographic evidence of osteolytic skeletal lesions [7] . In patients with true nonsecretory myeloma, the diagnosis was based on the presence of 30% monoclonal plasma cells in the bone marrow or the presence of a biopsy-proven plasmacytoma [7] . The clinical stages of the patients were classified according to the staging system of Durie-Salmon [8] . Only patients without previous diagnosis of MM were included into analysis. Patients with persistent proteinuria, hematuria, nephrotic syndrome, renal failure or tubulointerstitial dysfunction were clinically diagnosed with myeloma nephropathy. And patients with evidence of other renal diseases were excluded (for example advanced diabetes and hypertension with possible nephropathy, analgesic drug abuse, lupus, rheumatoid diseases, etc.) Renal failure was defined as a serum creatinine level ≥ 177 µmol/l [9] .
Clinical parameters such as the department in which the diagnosis was confirmed, gender, age, blood pressure, hemoglobin, blood urea nitrogen, serum creatinine, 
Results

Clinical characteristics of MM with or without renal involvement
The departments in which the diagnosis of MM was confirmed have been shown in We compared the clinical characteristics at the time of diagnosis between the MM patients with and without renal involvement ( Table 2 ). Patients with renal involvement had a higher systolic blood pressure (130.2± 18.7 mm Hg vs. 122.7 ± 14.2 mm Hg, P = 0.002), a lower hemoglobin level (84.9 ± 22.9 g/l vs. 94.1 ± 28.72g/l, P = 0.008) and a higher calcium level (2.4 ± 0.4 mmol/l vs. 2.3± 0.2 mmol/l, P = 0.012) than the levels in patients without renal involvement. Stage III disease was present in 110 (55.0%) patients in the renal involvement group and only 30 (36.2%) patients in the non-renal involvement group. No significant differences were detected in gender, age, albumin, proportion of plasma cells and incidence of bone destruction between patients with and without renal involvement.
Characteristics of renal involvement in MM
We have summarized the incidence and manifestations of renal involvement in MM in 
Characteristics of immunofixation electrophoresis and renal involvement
A total of 182 patients underwent immunofixation electrophoresis. The results of immunofixation electrophoresis in patients with and without renal involvement have been summarized in Table 5 ).
Characteristics of renal pathology and renal involvement
There were 9 patients with renal involvement underwent renal biopsy. The results of renal biopsy have been summarized in 
Discussion
MM is an age-related disease. In most studies, the reported age at onset is approximately 65 years. Palumbo A et al. [10] reported only 37% of patients with newly diagnosed disease are aged < 65 years, 26% are aged 65-74 years, and 37% are aged ≥ 75 years. Hasan Jalaeikhoo et al. [11] reported the mean age was 61.98 ± 11.44 years (range = 30-88 years), and the male: female ratio was 1.73. Our results were consistent with these findings: in our study, the median age at onset was 63 years, and the male: female ratio was 1.5:1. The youngest patient in our study was 36 years old.
In our study, 90(45.0%) patients were admitted to the Department of Nephrology.
And MM patients with renal involvement as the first symptom often do not exhibit the typical clinical manifestations of myeloma, such as hyperglobulinemia. From the Table 2 , we could find that patients with renal involvement had a lower globulin 9 level than the levels in patients without renal involvement. In the non-renal involvement group, 17 (20.5%) patients presented with bone pain as the first manifestation and were admitted in the Department Orthopedics. Other patients were admitted in the Departments of Oncology, Cardiology, Ophthalmology, Neurology, etc. The reason for this diversity in symptoms is that amyloid deposition in different organs or tissues causes dysfunction of these organs and tissues and leads to specific symptoms. In an analysis of light chain deposition disease (LCDD),
Pozzi et al. [9] found that 35% of LCDD cases were associated with extrarenal manifestations involving the heart (21%), which presented as congestive heart failure and arrhythmias, and the liver (19%), which could lead to portal hypertension. Involvement of the lung (pulmonary cystic disorder), gastrointestinal tract and neurological system was less frequent. The above findings indicate that the presenting symptoms of MM are diverse and can easily be misdiagnosed; therefore, every physician should be familiar with these symptoms.
Renal failure in MM is one of the most common complications, and 50% of MM patients are reported to have renal failure at the time of diagnosis [12, 13] . Hasan et al. [11] reported that in a group of 354 patients, serum creatinine levels were (2.04 ± 2.56) mg/dL , range in(0.6-26.6) mg/dL. MacLennan et al. [14] reported that in a group of 1,205 patients, serum creatinine levels were >130 μmol/l in 42% of patients, >200 μmol/l in 20% and >300 μmol/l in 12%. Korbet et al. reported that renal insufficiency (serum creatinine of 1.3 mg/dl) is found at presentation in almost 50% of patients with myeloma, and severe renal insufficiency (serum creatinine 2.0 to 2.5 mg/dl) is seen in 15 to 20% of cases [13] . In our study, however, the most common type of renal involvement was proteinuria and/or hematuria, followed by renal failure. In all, 94 (47.0%) patients presented with renal failure, the result is similar to those previously reported [12] [13] [14] . Moreover, MM patients with renal involvement had a higher degree of anemia, hypercalcemia and hypertension than patients without renal involvement. The incidence of stage III disease was also significantly higher in the renal involvement group than in the nonrenal involvement group. These data suggested that MM with renal involvement is a more serious condition, and this conclusion is consistent with the findings of other studies [14] . Suzuki K et al. [15] reported that hypercalcemia associated with osteolysis by myeloma cells is also causes of renal dysfunction.
We were analyzed the relationship between renal involvement and the results of immunofixation electrophoresis. In total, 182 patients, of which 135 were in the renal involvement group, underwent immunofixation electrophoresis. IgG, IgA, IgD, IgE nonsecretory and simple light chain disease was present in 52, 32, 1, 1, 4 and 45 patients, respectively, in the renal involvement group. IgG and IgA MM was found in 24 and 18 patients in the non-renal involvement group. Greipp et al. [8] reported the immunophenotyping results of 10,750 MM patients. They found that the IgG type accounted for 60% of patients, while the IgA, IgD and light chain types accounted for 24%, 3% and 11% of patients; the remaining 2% of patients had other immunophenotypes. Immunofixation electrophoresis of large samples of MM serum from abroad showed that IgG type accounted for 52%, and the IgA, IgM, IgD, kappa, and lambda types accounted for 21%, 0.5% , 2%, 9% and 7% of patients [16] . Our results were similar to these findings; the main immunophenotype of MM was IgG, followed by IgA and pure light chains.
Next, we analyzed the association of immunofixation electrophoresis results with clinical phenotype in patients with renal involvement. We found that 19 (36 [17] , which was higher than our study. In the literature, MM presenting as nephrotic syndrome is not common, although light chain and IgD MM can present as nephrotic syndrome [18] . It has been reported that patients of MM produce only light chains account for 40-60% of severe myeloma-associated kidney injury [19] .Consistent with this, our data also showed that patients with pure light chain MM were more prone to renal failure. The major cause of renal failure in patients with pure light chain disease is the overproduction of nephrotoxic light chains.
Heher et al. [20] reported that mechanisms are the result of nephrotoxic monoclonal Ig deposition in the kidneys and others are independent of Igs. However, in our data 36.5% patients with IgG MM and 68.8% patients with IgA MM in the renal involvement group presented with renal failure, indicating that the development of renal failure is not dependent solely on the concentration of light chains. Wirk et al. [21] reported that patients with large amounts of serum free light chains can have normal renal function, and patients with small concentrations of serum free light chains can present with renal failure. IgD and IgE overproduction is rare in MM. Only one patient in our study had IgD and IgE MM, which manifested as isolated proteinuria and renal failure. Tsakiris et al. [3] reported that IgD MM is almost invariably associated with Bence Jones light chain proteinuria and renal failure.
Renal biopsies in MM patients with renal dysfunction help defining the types of renal injury, which can influence the extent of aggressive therapy and predict possible outcome [22] .The common renal pathological type of MM are cast nephropathy, lightchain deposition disease and amyloidosis, and sometimes the three pathological types concurrence in the same kidney specimen. However, no coexistence of the three pathological types was observed in this group [23] . The single center of Mayo Clinic analyzed 190 cases of multiple myeloma kidney pathology, and the results showed that MCN accounted for 45%, renal amyloidosis 29%, and light chain deposition 26% [24] . SU Yu-Tai et al. [25] reported that the 46 cases of MM, cast nephropathy, renal amyloidosis and light-chain deposition disease accounted for 52.2%, 32.6%, and 4.3% patients, respectively. Our data also shows that cast nephropathy has the highest incidence, followed by renal amyloidosis, while light chain deposition disease was not found in any of the patients, which may due to small sample size. The patients of MM underwent renal biopsy for light-chain deposition disease is extremely rare, because of renal injury patterns other than cast nephropathy and amyloidosis can be very silent [26] .
We further analyzed the relationship between clinical phenotypes and results of renal biopsy in the renal involvement group. Cast nephropathy is mostly in stage Ⅱ, 24-h urinary protein and hypercalcemia is more obvious. However, renal amyloidosis is mostly in stage Ⅰ. Literature shows that the composition of urinary protein in MM patients with different renal pathological types is different. The main component of urinary protein in MM patients with cast nephropathy type is light chain, however, 70% of urinary protein in MM patients with renal amyloidosis type is albumin [27] . SU
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Yu-Tai et al. [25] reported that renal amyloidosis had the highest 24-hour urinary protein level and was more prone to hypoproteinemia-related manifestations, such as edema, nephrotic syndrome. Nasr SH et al. [28] reported that kappa chains tend to be more common in MCN and LCDD, which is consistent with our results.
Conclusions
In summary, this is the first study to report the proportion of MM patients who presented with renal involvement as the first manifestation and were admitted in the Department of Nephrology. These patients often did not exhibit the typical clinical manifestations of myeloma. We have also reported, in detail, the characteristics of immunofixation electrophoresis, renal pathology and manifestations of renal involvement. These data should help nephrologists hvae a deeper understanding of MM associated with renal involvement.
The main limitation of our study was that there was small sample size underwent renal biopsy. Diagnosis of multiple myeloma does not require renal biopsy, however, a biopsy based diagnosis is important in the evaluation of patients with myeloma because each of the renal lesions has its own therapeutic and prognostic implications. 
